USA Weekly has been interviewing companies from around the world to discover what challenges they are facing in their businesses. We also asked each company to share business advice they would give to a younger version of themselves.
Below is our interview with Sam Santhosh, Founder, Chairman and Global CEO at MedGenome:
What does your company do?
MedGenome is a genomics research and diagnostics company with a mission to improve global health by decoding the genetic information contained in an individual’s genome. Its unique access to Indian genomics data with clinical and phenotypic details provides insights into the biology of complex diseases to facilitate research leading to personalized health care. MedGenome is the market leader for genomic diagnostics in South Asia and a leading provider of genomics research services globally. MedGenome is also a founding member of GenomeAsia 100K initiative to sequence 100,000 Genomes in South, North and East Asia.
MedGenome presented a poster on its study of potential cancer vaccines for Lynch Syndrome patients
Attendees at the 2018 Molecular Medicine Tri-Conference heard MedGenome, a global leader in genomics research and a partner to pharma/biotech companies and academic research institutions conducting complex disease biomarker-identification projects, describe its study of potential cancer vaccines for patients with Lynch syndrome. Lynch syndrome is an inherited condition linked to higher risk of various forms of cancer, including a 70 percent to 80 percent lifetime risk of developing colorectal cancer, with a mean onset age of 45 years.
Dr. Papia Chakraborty, senior scientist and head of immuno-oncology at MedGenome, spoke on “A Personalized Cancer Vaccine Approach to Treat Lynch Syndrome.”
Genomic diagnostics and research firm MedGenome plans to ramp up its research in the single-cell and immuno-oncology spaces while continuing to make inroads in the clinical genomic testing market in India.
The company has next-generation sequencing laboratories in Bangalore, India; Foster City, California; and Singapore. MedGenome CEO Sam Santhosh said that the Bangalore lab is primarily a diagnostics lab, while its large research projects are run mainly from its Foster City laboratory.
Last year, the firm raised $30 million in a Series C financing round, which it has used in part to expand its Foster City lab and purchase new technology, most notably 10x Genomics’ Chromium system and Illumina’s NovaSeq instrument.
Santhosh said that the company plans to focus upcoming research in the immuno-oncology space, including using single-cell sequencing techniques to analyze the tumor microenvironment.
MedGenome has expanded its sequencing capacity at its Foster City, Calif., headquarters laboratory, adding HiSeqX and NovaSeq 6000 platforms to meet the rising demands for Next Generation Sequencing (NGS) in research and clinical settings. The new additions increase MedGenome’s data-generation capability by a factor of five. Additionally, availability of a wide range of sequencing platforms gives MedGenome the flexibility to provide customized services at scale – thousands of whole genomes a month — and deliver high-quality data quickly at a competitive price. The NGS lab has also added sample-processing automation from Agilent to support the sequencing capacity.
“Adding the new platforms in our California lab gives us the throughput and scale to take on large genomic projects that are rapidly transforming the clinical trial landscape by enabling precision medicine and personalized therapy particularly in immuno-oncology, neurological disorders and rare diseases,” said Sam Santhosh, founder, chairman and global CEO of MedGenome. “Our ability to deliver high-quality data for large-scale genomics projects in a timely manner helps our clients to accelerate their preclinical and clinical research programs.”